Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Travere Therapeutics gains as EU backs kidney disease therapy [Seeking Alpha]

CSL LTD SP/ADR (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
Company Research Source: Seeking Alpha
Agency (EMA), endorsed conditional marketing authorization for its kidney disease therapy sparsentan. According to the company and CSL Vifor, its commercial partner for sparsentan, the EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of the drug for adults with a rare kidney disease called IgA nephropathy. In 2021, San Diego, California-based Travere ( TVTX ) granted exclusive commercialization rights for sparsentan to CSL Vifor, a unit of Australian biotech CSL Limited ( OTCQX:CSLLY ), for regions including Europe. The CHMP recommendation will next be reviewed by the European Commission (EC) before a final decision on marketing authorization, which is expected in Q2 2024. Recommended For You Recommended For You Related Stocks In The News Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
CSLLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
CSLLY alerts

from News Quantified
Opt-in for
CSLLY alerts

from News Quantified